{
    "name": "belumosudil",
    "comment": "Rx",
    "other_names": [
        "Rezurock"
    ],
    "classes": [
        "ROCK Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/rezurock-belumosudil-4000186",
    "pregnancy": {
        "common": [
            "Based on animal studies and mechanism of action, fetal harm may occur ",
            "No human data are available on use in pregnant females to evaluate for drug-associated risks",
            "Verify pregnancy status of females of reproductive potential before initiating "
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "  ",
                    "  ",
                    "Use effective contraception during treatment and for at least 1 week after last dose",
                    "If used during pregnancy or if patient becomes pregnant during treatment, inform patient of potential hazard to fetus ",
                    "  ",
                    "  ",
                    "Use effective contraception during treatment and for at least 1 week after last dose "
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on animal findings, male or female fertility may be impaired; effects on fertility are reversible "
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Administration of belumosudil to pregnant rats and rabbits during organogenesis resulted in adverse developmental outcomes, including alterations to growth, embryofetal mortality, and embryofetal malformations at maternal exposures approximately ≥3x (rat) and ≥0.07x (rabbit) the human exposure (AUC) at the recommended dose "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data available on drug presence or its metabolites in human milk or effects on breastfed children, or milk production",
            "Advise lactating females not to breastfeed during treatment and for at least 1 week after last dose "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Can cause fetal harm"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Substrate of CYP3A4 and P-gp (in vitro)",
                        "In vitro studies",
                        "Inhibits BCRP, P-gp, and OATP1B1 at clinically relevant concentrations",
                        "Inhibits CYP1A2, CYP2C19, CYP2D6, UGT1A1, and UGT1A9",
                        "Strong CYP3A4 inducers",
                        "Increase to 200 mg PO BID",
                        "Strong CYP3A inducers decrease exposure and effects of belumosudil",
                        "Proton pump inhibitors",
                        "Increase to 200 mg PO BID",
                        "Proton pump inhibitors decrease exposure and effects of belumosudil "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bexarotene",
            "description": {
                "common": "bexarotene will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brigatinib",
            "description": {
                "common": "brigatinib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clobazam will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "dexlansoprazole will decrease the level or effect of belumosudil by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will increase the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole will decrease the level or effect of belumosudil by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "lansoprazole will decrease the level or effect of belumosudil by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "mobocertinib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will decrease the level or effect of belumosudil by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pantoprazole",
            "description": {
                "common": "pantoprazole will decrease the level or effect of belumosudil by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "pexidartinib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "rabeprazole will decrease the level or effect of belumosudil by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with proton pump inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telotristat ethyl",
            "description": {
                "common": "telotristat ethyl will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infection",
            "percent": "53"
        },
        {
            "name": "unspecified pathogen",
            "percent": "46"
        },
        {
            "name": "Asthenia",
            "percent": "42"
        },
        {
            "name": "Nausea",
            "percent": "35"
        },
        {
            "name": "Diarrhea",
            "percent": "33"
        },
        {
            "name": "Dyspnea",
            "percent": "30"
        },
        {
            "name": "Cough",
            "percent": "27"
        },
        {
            "name": "Edema",
            "percent": "23"
        },
        {
            "name": "Hemorrhage",
            "percent": "22"
        },
        {
            "name": "Abdominal pain",
            "percent": "22"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "21"
        },
        {
            "name": "Hypertension",
            "percent": "21"
        },
        {
            "name": "Headache",
            "percent": "19"
        },
        {
            "name": "Viral infection",
            "percent": "18"
        },
        {
            "name": "Pyrexia",
            "percent": "17"
        },
        {
            "name": "Muscle spasm",
            "percent": "17"
        },
        {
            "name": "Decreased appetite",
            "percent": "16"
        },
        {
            "name": "Bacterial infection",
            "percent": "16"
        },
        {
            "name": "Dysphagia",
            "percent": "15"
        },
        {
            "name": "Arthralgia",
            "percent": "12"
        },
        {
            "name": "Nasal congestion",
            "percent": "12"
        },
        {
            "name": "Rash",
            "percent": "11"
        },
        {
            "name": "Pruritus",
            "percent": "83"
        },
        {
            "name": "ALT increased",
            "percent": "83"
        },
        {
            "name": "Creatinine increased",
            "percent": "83"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "82"
        },
        {
            "name": "Calcium decreased",
            "percent": "82"
        },
        {
            "name": "Potassium increased",
            "percent": "82"
        },
        {
            "name": "Platelets decreased",
            "percent": "80"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "79"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "76"
        },
        {
            "name": "Phosphate decreased",
            "percent": "62"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "47"
        },
        {
            "name": "Gamma glutamyl transferase",
            "percent": "29"
        },
        {
            "name": "GGT",
            "percent": "28"
        },
        {
            "name": "increased",
            "percent": "21"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "12"
        },
        {
            "name": "Phosphate decreased",
            "percent": "11"
        },
        {
            "name": "GGT increased",
            "percent": "16"
        },
        {
            "name": "Calcium decreased",
            "percent": "13"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "11"
        },
        {
            "name": "Infection",
            "percent": "13"
        },
        {
            "name": "unspecified pathogen",
            "percent": "11"
        },
        {
            "name": "Max post Lymphocytes decreased",
            "percent": "10"
        },
        {
            "name": "GGT increased",
            "percent": "9"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "8"
        },
        {
            "name": "GGT increased",
            "percent": "7"
        },
        {
            "name": "Platelets decreased",
            "percent": "7"
        },
        {
            "name": "Alkaline phosphate increased",
            "percent": "4"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "7"
        },
        {
            "name": "Potassium increased",
            "percent": "5"
        },
        {
            "name": "ALT increased",
            "percent": "5"
        },
        {
            "name": "Creatinine increased",
            "percent": "5"
        },
        {
            "name": "Hypertension",
            "percent": "4"
        },
        {
            "name": "Diarrhea",
            "percent": "4"
        },
        {
            "name": "Dyspnea",
            "percent": "4"
        },
        {
            "name": "Hemorrhage",
            "percent": "4"
        },
        {
            "name": "Viral infection",
            "percent": "4"
        },
        {
            "name": "Bacterial infection",
            "percent": "2"
        },
        {
            "name": "Asthenia",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "1"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "1"
        },
        {
            "name": "Arthralgia",
            "percent": "1"
        },
        {
            "name": "Edema",
            "percent": "7"
        },
        {
            "name": "Pyrexia",
            "percent": "5"
        },
        {
            "name": "Abdominal pain",
            "percent": "4"
        },
        {
            "name": "Decreased appetite",
            "percent": "2"
        },
        {
            "name": "Max post Phosphate decreased",
            "percent": "1"
        },
        {
            "name": "Platelets decreased",
            "percent": "1"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "1"
        },
        {
            "name": "ALT increased",
            "percent": "7"
        },
        {
            "name": "Calcium decreased",
            "percent": "5"
        },
        {
            "name": "Potassium increased",
            "percent": "4"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "2"
        },
        {
            "name": "Phosphate decreased",
            "percent": "1"
        },
        {
            "name": "Platelets decreased",
            "percent": "1"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "1"
        },
        {
            "name": "ALT increased",
            "percent": null
        },
        {
            "name": "Calcium decreased",
            "percent": null
        },
        {
            "name": "Potassium increased",
            "percent": null
        },
        {
            "name": "Hemoglobin decreased",
            "percent": null
        }
    ]
}